Author Keywords: chronic depression; clinical trial; dysthymia; medication treatment; serotonergic antidepressants 相似文献
全文获取类型
收费全文 | 2930篇 |
免费 | 229篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 100篇 |
妇产科学 | 108篇 |
基础医学 | 414篇 |
口腔科学 | 147篇 |
临床医学 | 344篇 |
内科学 | 624篇 |
皮肤病学 | 60篇 |
神经病学 | 243篇 |
特种医学 | 90篇 |
外科学 | 330篇 |
综合类 | 8篇 |
一般理论 | 3篇 |
预防医学 | 256篇 |
眼科学 | 33篇 |
药学 | 120篇 |
中国医学 | 2篇 |
肿瘤学 | 243篇 |
出版年
2023年 | 52篇 |
2022年 | 82篇 |
2021年 | 199篇 |
2020年 | 120篇 |
2019年 | 151篇 |
2018年 | 141篇 |
2017年 | 104篇 |
2016年 | 93篇 |
2015年 | 114篇 |
2014年 | 138篇 |
2013年 | 166篇 |
2012年 | 252篇 |
2011年 | 229篇 |
2010年 | 89篇 |
2009年 | 69篇 |
2008年 | 150篇 |
2007年 | 129篇 |
2006年 | 118篇 |
2005年 | 103篇 |
2004年 | 102篇 |
2003年 | 98篇 |
2002年 | 68篇 |
2001年 | 22篇 |
2000年 | 17篇 |
1999年 | 16篇 |
1998年 | 18篇 |
1997年 | 16篇 |
1996年 | 12篇 |
1995年 | 7篇 |
1994年 | 11篇 |
1993年 | 10篇 |
1992年 | 16篇 |
1991年 | 16篇 |
1990年 | 8篇 |
1989年 | 15篇 |
1988年 | 23篇 |
1987年 | 22篇 |
1986年 | 19篇 |
1985年 | 18篇 |
1984年 | 11篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 9篇 |
1979年 | 7篇 |
1977年 | 4篇 |
1976年 | 5篇 |
1975年 | 9篇 |
1966年 | 4篇 |
1938年 | 5篇 |
1937年 | 8篇 |
排序方式: 共有3164条查询结果,搜索用时 15 毫秒
1.
Camille Veit 《Annales médico-psychologiques》2019,177(4):347-351
Objectives
This paper introduces some epistemology about mental health developments and how it leads to reconsider the landscape of clinical practices.Materials
From an epistemological point of view, the author reviews several writings about mental hygiene going back to the nineteenth century. It clarifies the common roots between mental hygiene and mental health. Then, the article examines the first World Health Organization's reports, that shed light on psychiatric and political issues in the middle of the twentieth century, which allows to reach out the foundations of mental health as a discursive practice.Results
The review of the developments from “mental hygiene” to “mental health” highlights a general climate of redesign on many points: Mental health as a discursive space is characterized by an expansion of its address field. It is not only addressed to specialists, psychiatrist and psychiatric patients, but also, and above all, to every citizen. Psychic suffering, as far as mental illness, is part of a larger whole including what preserves or deteriorates the proper functioning of an individual, within society. Mental health is at the crossroads of financial, political, citizen's rights and social interests. Contemporary mental health relies on the objectives of prevention and promotion. Clinical practices are organized by some discourses with mental health as a key word. At the turn of 2000s, French psychiatry has been impacted by many shuffles in health policies. However, the roots of these restructuring are not new, as they update an old interest in safeguarding public health, funds and welfare. Psychic suffering and mental illness recently enter the field of “psychic disability”. It brought social benefits such as financial assistance from the state. It may also contribute to the campaigns of awareness-raising and destigmatization among the public opinion. However, financial and subjective effects do not perfectly match. In other words, the benefits listed above should not lead to desert the listening of the users’ experience in its singularity.Conclusions
The developments of mental health point out a reorganization in the psychiatric field and open new clinical challenges. If the spaces of singularity and universal are in a permanent relationship, the political and economic sides cannot answer or evacuate the subjectivity posed by the subject and his suffering. It should lead to focus on a clinical practice driven by a subtle listening, which does not exclude psychopathology and recognizes the importance of alterity. 相似文献2.
J N Munck 《Journal of clinical oncology》2003,21(8):1648; author reply 1648-1648; author reply 1649
3.
R Yassa C Nastase Y Camille M Henderson L Belzile F Beland 《The Journal of clinical psychiatry》1987,48(7):281-283
Although carbamazepine is known to cause hyponatremia, no previous reports have indicated an interaction between carbamazepine and a diuretic. Two patients are described who were treated with this combination and developed symptomatic hyponatremia, which cleared when both drugs were discontinued in one patient and when the diuretic was discontinued in the second patient. The possible mechanisms of action of carbamazepine-induced hyponatremia are discussed. 相似文献
4.
Andr Mas Hassan Jaaba Franois Schu Anna M. Belu Camille M. Kassis Richard W. Linton Joseph M. Desimone 《Macromolecular chemistry and physics.》1997,198(11):3737-3752
Homogeneous and stable layers were deposited through allylamine plasma polymerization (75 W, 100 Pa, 15 min) onto poly[(3-hydroxybutyric acid)-co-(3-hydroxyvaleric acid)] (91 : 9 wt.-%) (P(HB-co-9%HV)) film surfaces, XPS analysis using take-off angles of 20° and 70° and performed 10 days and 20 days after plasma treatment gives information on the composition (in atom%) of the modified surface: C, 62.74; N, 19.60; O, 17.65. The unexpected oxygen percentage is weaker if argon plasma pretreatment (25 W, 40 Pa, 5 min) is applied. Then, a succinct mechanism is proposed. The study of changes in element ratios and binding energy values shows that the majority of incorporated functional groups seem to be amide and imine groups. 相似文献
5.
Jesse Rosenthal Camille Hemlock David J. Hellerstein Phillip Yanowitch Karen Kasch Cynthia Schupak Lisa Samstag Arnold Winston 《Progress in neuro-psychopharmacology & biological psychiatry》1992,16(6):933-941
Rosenthal, Jesse et al. A Preliminary Study of Serotonergic Antidepressants in the Treatment of Dysthymia. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1992, 16(6): 933–941.
1. 1. There is increasing evidence that antidepressants may alleviate symptoms of dysthymia, but few prior studies on selective serotonergic agents.
2. 2. Twenty patients meeting criteria for dysthymia, but not meeting criteria for major depression, received open label trials of a serotonergic antidepressant, either fluoxetine or trazodone.
3. 3. Seventeen (85%) completed three-month medication trials, and of these, twelve (70.6% of completers) responded to treatment. Seven (41.2% of completers) were still in remission on followup at five months.
4. 4. Both fluoxetine and trazodone were well tolerated in dysthymics, and showed similar short-term effectiveness in treating dysthymic symptoms.
6.
C von Kalle J Wolf A Becker A Sckaer M Munck A Engert U Kapp C Fonatsch D Komitowski W Feaux de Lacroix 《International journal of cancer. Journal international du cancer》1992,52(6):887-891
No animal model exists for the in vivo growth of Hodgkin's-lymphoma-derived cells. Neither unmanipulated Hodgkin's-disease(HD)-derived cell lines nor primary biopsy tissue could be grown in nude mice. Since the severe combined immunodeficient (SCID) mouse has been reported to be a better recipient for transplanted human lymphatic tissue than the nude mouse, we tested whether SCID mice provide suitable conditions for the in vivo growth of HD cell lines. Tumorigenicity of HD cells was tested in untreated and pre-treated SCID mice and in another combined immunodeficient mouse strain, beige/nude/X-linked immunodeficient (BNX) mouse. SCID mice supported in vivo growth of the 6 HD cell lines tested (L428, L540, L591, DEV, HD-LM2, KM-H2). Only one of the 6 lines (DEV) was tumorigenic in BNX mice. No HD cell line proliferated in T-cell-deficient nude mice. Thus, in vivo growth of HD cell lines appeared to be related to the degree of host immunodeficiency. Additional growth supportive treatments such as fibrosarcoma co-transplantation, intraperitoneal mineral oil injection or immunosuppressive pre-treatment (anti-asialo-GMI-antibody injection) permitted growth of 3 additional HD cell lines in BNX mice. The immunophenotype and karyotype of explanted graft cells were identical to the original cell lines. Our experiments describe an effective and reproducible xenograft model for growth of Hodgkin's-disease-derived cell lines. This may be of value for elucidating the growth characteristics of Hodgkin's-lymphoma-derived cells as well as for testing new therapeutic regimens. 相似文献
7.
Luis H. Ramirez Morbize Juliéron Marc Bonnay Serge Koscielny Zhongxin Zhao Alain Gouyette Jean-Nicolas Munck 《Investigational new drugs》1995,13(1):51-53
Suramin is an antitrypanosomal compound with confirmed efficacy against several human malignancies. It is generally assumed
that its mechanism of action includes the interaction with different growth factors, unlike most of the anticancer drugs.
Its anticancer activity has not been testedin vivo against squamous cell carcinoma. The purpose of this study was to assess the efficacy and toxicity of suraminin vivo andin vitro on the VX2 tumor model at therapeutic monitored plasma concentrations. We determined the pharmacokinetics of suramin in rabbits,
and modelized its administration in order to obtain plasma concentrations between 150 and 300 μg/ml throughout the treatment
course of 3 weeks. Under these conditions, antitumor effects of suramin were evaluatedin vivo by comparing liver tumor involvement in suramin-treated and control rabbits. Liver involvement was quantified by image analysis
andin vitro effects were also determined at the same concentrations.In vivo, suramin promoted liver tumor growth significantly (p<0.05), compared to untreated controls.In vitro, suramin significantly stimulated tumor cell growth at concentrations above 200 μg/ml (p<0.01). Suramin may have stimulatory
effects on tumor growth in squamous cell carcinoma at relevant plasma drug concentrations. Caution should be taken in further
trials in patients with squamous cell carcinomas. 相似文献
8.
A survey of newborn screening for cystic fibrosis in Europe. 总被引:2,自引:0,他引:2
Kevin W Southern Anne Munck Rodney Pollitt Georges Travert Luisa Zanolla Jeannette Dankert-Roelse Carlo Castellani 《Journal of cystic fibrosis》2007,6(1):57-65
BACKGROUND: Cystic fibrosis (CF) is a recessively inherited condition caused by mutation of the CFTR gene. Newborn infants with CF have raised levels of immuno-reactive trypsinogen (IRT) in their serum. Measurement of IRT in the first week of life has enabled CF to be incorporated into existing newborn screening (NBS) blood spot protocols. However, IRT is not a specific test for CF and NBS therefore requires a further tier of tests to avoid unnecessary referral for diagnostic testing. Following identification of the CFTR gene, DNA analysis for common CF-associated mutations has been increasingly used as a second tier test. The aim of this study was to survey the current practice of CF NBS programmes in Europe. METHOD: A questionnaire was sent to 26 regional and national CF NBS programmes in Europe. RESULTS: All programmes responded. The programmes varied in number of infants screened and in the protocols employed, ranging from sweat testing all infants with a raised first IRT to protocols with up to four tiers of testing. Three different assays for IRT were used; in the majority (24) this was a commercially available kit (Delfia). A number of programmes employed a second IRT measurement in the 4th week of life (as the IRT is more specific at this point). Nineteen programmes used DNA analysis for common CFTR mutations on samples with a raised first IRT. Three programmes used a second IRT measurement on infants with just one recognised mutation to reduce the number of infants referred for sweat testing. Referral to clinical services was prompt and diagnosis was confirmed by sweat testing, even in infants with two recognised mutations in most programmes. Subsequent clinical pathways were less uniform. Multivariate analysis demonstrated a relationship between the age of diagnosis and the timing of the first IRT. More sweat tests were undertaken if the first IRT was earlier and the diagnosis was later. CONCLUSIONS: Annually these programmes screen approximately 1,600,000 newborns for CF and over 400 affected infants are recognised. The findings of this survey will guide the development of European evidence based guidelines and may help new regions or nations in the development and implementation of NBS for cystic fibrosis. 相似文献
9.
10.
The authors present a prevalence study of tardive dyskinesia (TD) in the course of antidepressant therapy. Of the 50 patients evaluated, three developed TD. TD developed rapidly and in a short period of time. Withdrawal of antidepressant improved TD in two patients. The literature on TD developing in the course of antidepressant therapy is reviewed, and the different etiological theories are examined. 相似文献